SEC Form 4 · accession 0001209191-18-052512
TRANSENTERIX INC. · TRXC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William N Starling Jr.
Director
Period of report
Sep 25, 2018
Accepted (ET)
Sep 27, 2018 · 8:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876378
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 25, 2018 | S | 1,700,000 | $6.40 | D | 3,618,969 | I | See Footnote |
| Common StockF1,F3 | Sep 26, 2018 | S | 775,000 | $6.26 | D | 2,843,969 | I | See Footnote |
| Common StockF1,F4 | Sep 27, 2018 | S | 1,139,649 | $6.13 | D | 1,704,320 | I | See Footnote |
| Common StockF5 | holding | — | — | — | 235,738 | I | See Footnote | |
| Common StockF6 | holding | — | — | — | 213,415 | I | By Trust | |
| Common Stock | holding | — | — | — | 66,987 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Synergy Life Science Partners, L.P., the holder of these shares, sold an aggregate of 1,700,000 shares of TransEnterix stock on September 25, 2018, an aggregate of 775,000 shares on September 26, 2018, and an aggregate of 1,139,649 shares on September 27, 2018. The reporting person is a control person of the General Partner of Synergy Life Science Partners, L.P. The reporting person disclaims any beneficial ownership of the shares of TransEnterix stock owned by Synergy Life Science Partners, L.P. and has no pecuniary interest in such shares.
- F2The sale price reported in Column 4 is a weighted average price. These shares were sold by Synergy Life Science Partners, L.P. in multiple transactions at prices ranging from $6.25 to $6.90 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F3The sale price reported in Column 4 is a weighted average price. These shares were sold by Synergy Life Science Partners, L.P. in multiple transactions at prices ranging from $6.20 to $6.475 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F4The sale price reported in Column 4 is a weighted average price. These shares were sold by Synergy Life Science Partners, L.P. in multiple transactions at prices ranging from $6.05 to $6.205 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- F5Shares of common stock held by Synecor, LLC. The reporting person is the chief executive officer of Synecor, LLC.
- F6Shares of Common Stock held by W. Starling and D. Starling, Trustees of the Starling Family Trust, UDT August 15, 1990.